Press Release: Gardasil & Cervarix - Opening the Door for New Viral Infections

[Guest guest]

Press Release

For Immediate Release

Contact: Carol Botha

Email: publicrelations@...<?xml:namespace prefix = o ns =

" urn:schemas-microsoft-com:office:office " />

Gardasil & Cervarix - Opening the Door for New

Viral Infections

Are Strains Targeted by the Vaccines Replaced by other HPV

Viruses?

SANE Vax Inc. April 1, 2011. Immunologist

Charlotte Haug, MD PhD, MSc and Editor-in-Chief, Tidsskrift for Den

norske legeforening (The Journal of the Norwegian Medical Association)

raises an interesting question that has yet to be considered by the FDA,

CDC or the medical community. What happens if other strains of HPV

replace strains 16 or 18 after vaccination by Gardasil or Cervarix?

If the vaccines are effective will the replacement viruses cause less

disease or more disease?

SANE Vax Inc. is demanding Gardasil and Cervarix be taken off the market

until these questions are answered in an independent study on HPV vaccine

safety and efficacy.

Dr. Haug presented ‘To vaccinate or not – a different point of

view’ at the 1st Nordic Gynecologic Meeting on HPV

vaccination in March 2010 where she raised these questions. She stated

that “Nature never leaves a void” and cited two studies that raise

concern about viral replacement:

Alaska native children are experiencing replacement invasive

pneumococcal disease just four years after vaccination (JAMA 2007)

1.

HPV prevalence in Colombian women with cervical cancer: implications for

vaccination in a developing country (PubMed.gov) 2.

Murillo et al 2009 revealed in this study that:

Age specific HPV type prevalence revealed significant

differences

Multiple high-risk infections appeared in 17% of

the cases and represent a chance of replacement

Highlight the role of HPVs other than 16/18 that

will affect potential vaccine impact

Multiple high-risk infections appeared in

16.6% of cases and represent a chance of replacement. Age-specific HPV

prevalence and multiple high-risk infections might influence vaccine

impact. Both factors highlight the role of HPVs other than 16/18, which

should be considered in cost-effectiveness analyses for potential vaccine

impact.

The graph below clearly shows that HPV 16 & 18 are not even

prevalent in Colombian women until their mid-20’s – long after vaccine

efficacy has worn off if a girl is administered Gardasil or Cervarix in

her adolescent years.

What are these vaccines doing? What

are they effective against? And why are they on the market before these

questions are answered?

SANE Vax, Inc. wants to remind medical

consumers that viral replacement is not a new concept.

The medical community is currently looking for ways

to combat super-bacteria such as MRSA –

(Methicillin-resistant Staphylococcus aureus) infection caused by a

strain of staph bacteria that's become resistant to the antibiotics

commonly used to treat ordinary staph

infections.3.

When antibiotics were invented, no one understood bacterial and viral

mechanisms of action; they have only one purpose –and that is to survive.

Staph and strep bacteria mutated to survive in the suppressive

environment created by the use, and abuse, of antibiotics. These

'super-strains' now pose a substantial risk to human survival in those

exposed. Will the same thing happen as various strains of HPV in vaccines

are suppressed?

The Colombian study raises another issue that needs to be addressed and

that is whether HPV 16 & 18 are the dominant viral strains in the

targeted demographic.

A May 2008 study on High-risk and multiple human papillomavirus (HPV)

infections in cancer-free Jamaican women presented at the Second

Annual International African-Caribbean Cancer Consortium Conference cited

that:

The most important finding was that unlike the genotype distribution

patterns seen in North America, Europe and some parts of Asia [11,12] HPV

types 16 and 18 were not the most common high-risk genotypes. In our

population, HPV types 45 and 58 accounted for 40.5% of the genotypes.

Other groups, e.g. Trinidad and Tobago, Cuba and parts of Africa [13-18],

have also reported different distributions of genotypes indicating that

types 16 and 18 were not predominant in these populations. The recently

developed prophylactic vaccines may therefore not be efficacious in our

and similar populations.4.

Why is Gardasil marketed

globally through the Gardasil Access Program when HPV 16 & 18 may not

even be prevalent amongst the targeted populations? 5.

The GARDASIL Access Program is

pleased to announce that, following the November 2010 Advisory Board

meeting, three new applicants were recommended for participation in the

program. Since inception of the program, organizations and institutions

in Bhutan, Bolivia, Cambodia, Cameroon, Georgia, Ghana, Haiti, Honduras,

India, Kenya, Kiribati, Lesotho, Moldova, Nepal, Nicaragua, Nigeria,

Papua New Guinea, Tanzania, Uganda, and Uzbekistan have been approved to

receive more than 1 million doses of GARDASIL to gain operational

experience in the design and implementation of HPV vaccination projects

in their countries.

Interesting to note that Jamaica is not listed as one of the eligible

countries for the Access Program? Is this because of the study?

6.

The conclusion of yet another study published in 2006, Human

Papillomavirus Infections with Multiple Types and Risk of Cervical

Neoplasia states that infections with multiple HPV types

seem to act synergistically in cervical carcinogenesis.7.

Perhaps this is why the Vaccine Adverse Reaction System (VAERS) is

beginning to report numerous cases of abnormal pap smears, genital warts,

HPV infections and even cervical cancer post-HPV vaccination:

·

376 abnormal pap smears post HPV

vaccination

·

108 reports of anogenital warts found after

HPV vaccination

·

224 reports of papillomavirus infections

found after HPV vaccination

·

41 reports of cervical cancer after HPV

vaccination

Clearly there is a problem with the HPV vaccines – and it is the

uninformed medical consumers who will suffer. Clearly, not enough

studies have been conducted on the safety and efficacy of the HPV

vaccines in targeting only two carcinogenic strains of HPV – that might

not even be prevalent in many populations.

According to the CDC, “While there are well-established cancer registries

in the United States, it will take decades before the impact of vaccine

on cervical cancer is observed. More proximal measures of vaccine impact

include outcomes such as prevalence of HPV vaccine types, incidence of

cervical pre-cancers and genital warts.” 8.

SANE Vax, Inc. believes that there is no evidence to support the

hypothesis that Gardasil or Cervarix effectively protects against

cervical cancer. Indeed, the May 2006 FDA VRBPAC supports this conclusion

by stating that if a woman is previously exposed to vaccine relevant HPV

and is vaccinated anyway, her chances of getting cervical cancer increase

44.6% post Gardasil and 32.5% post Cervarix. 9.

Source:

Invasive Pneumococcal Caused by

Nonvaccine Serotypes Among Alaska Native Children with High Levels of

7-Valent Pneumococcal Conjugate Vaccine

Coverage,

JAMA. 2007;297(16):1784-1792. doi:

10.1001/jama.297.16.1784

http://jama.ama-assn.org/content/297/16/1784 HPV prevalence in Colombian women with cervical cancer: implications

for vaccination in a developing country, Infect Dis Obstet

Gynecol. 2009;2009:653598. Epub 2009 Dec 20,

http://www.ncbi.nlm.nih.gov/pubmed/20052389 MRSA Definition, Mayo Clinic,

http://www.mayoclinic.com/health/mrsa/DS00735 High-risk and multiple human papillomavirus (HPV) infections in

cancer-free Jamaican women, Proceedings from the Second Annual

International African-Caribbean Cancer Consortium Conference; Miami, FL

USA 12–13 May 2008,

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638456/ Gardasil Access Program,

http://gardasil-access-program.org/ Gardasil Access Program List of Eligible Countries,

http://gardasil-access program.org/section/145 Human Papillomavirus Infections with Multiple Types and Risk of

Cervical Neoplasia, Cancer Epidemiology Biomarkers and Prevention, May

2006,

http://cebp.aacrjournals.org/content/15/7/1274.abstract Post-licensure monitoring of HPV vaccine in the United States,

Centers for Disease Control and Prevention, Vaccine. 2010 Jul

5;28(30):4731-7. Epub 2010 Feb 25,

http://www.ncbi.nlm.nih.gov/pubmed/20188681 May 2006 VRBPAC Report,

http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf

http://www.naturalnews.com/031901_Gardasil_vaccines.html

Carol Botha,

Vice-President Public Relations, SANE Vax, Inc.

Health Educator, Broadcast Journalist

Internationally Recognized Expert on Women’s Hormone Cycles

Holy Hormones Honey -The Greatest Story Never Told!

http://holyhormones.com/

http://sanevax.org

Sheri Nakken, former R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start March 25 & April 1